Cencora Inc. (COR) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.

Total Revenue Chart for Cencora Inc.

Cencora Inc. (COR) revenue for FY2025 was USD 321.3B, a 9.3% change from FY2024. Cencora Inc.'s revenue grew from USD 4.3B in 1994 to USD 321.3B in 2025 (7369.7% over 31 years). Earnings per share grew from USD 4.04 in 2019 to USD 7.96 in 2025 (97.2%). Revenue compound annual growth rate: 5-year CAGR of 11.1%, 10-year CAGR of 9.0%, 20-year CAGR of 9.3%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$62.02B
Implied Share Price
$325.01
Enterprise Value
$70.78B
Revenue (TTM)
$332.77B
EBITDA
$5.33B
Profit Margin
0.79%
Trailing P/E
24.11
Forward P/E
15.55
Price/Book (MRQ)
17.83
Price/Sales (TTM)
0.19
EV/EBITDA
14.07
EV/Revenue
0.22
Dividend Yield
0.17%
Book Value
$17.46
Free Cash Flow (FY2025)
$3.21B
Free Cash Flow Yield
5.17%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.